Intercept Platelet Pathogen Reduction Sets
Closed Pre-Solicitation Posted
- Solicitation number
- W81K0221Q0194
- Agency
- Medical Command Department of the Army, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Place of performance
- Tripler Army Medical Center, Hawaii 96859, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Regional Health Contracting Office - Pacific, in support of Tripler Army Medical Center (TAMC) in Hawaii, intends to make a sole source award to Cerus Corporation for the purchase of Cerus Intercept Platelet Pathogen Reduction Sets. These platelet pathogen reduction sets utilize a chemical agent activated by ultraviolet light to bind nucleic acids and prevent replication of DNA and cells. They are used in conjunction with platelets and plasma in an Intercept processing set. The authority permitting this award without full and open competition is cited in FAR 13.106-1(b)(1)(i) as Cerus Corporation is the sole provider that can meet the government's need.
There is no set-aside designation for this pre-solicitation notice. Cerus Corporation is identified as the potential incumbent and current contractor for these Intercept Platelet Pathogen Reduction Sets. The authority cited permits a sole source award when there is only one source available to meet the government's requirement. No potential award values or quantities are provided, but the notice has a due date of July 16, 2021 for any responses regarding Cerus Corporation's ability to fulfill the government's need.
Notice text
The Regional Health Contracting Office – Pacific, in support of Tripler Army Medical Center (TAMC), Hawaii, intends to make a sole source award to Cerus Corporation for the purchase of Cerus Intercept Platelet Pathogen Reduction Sets. These supplies are the only ones that can meet the Government’s need. Cerus Corporation is the sole provider of the Cerus Intercept Platelet Pathogen Reduction Sets which uses a chemical agent (amotosalen) that is activated by ultraviolet A (UVA) light to bind nucleic acids so that DNA cannot replicate and thus the cell cannot replicate. The platelet pathogen reduction sets is used in conjunction with platelets and plasma in an Intercept processing set. The authority permitting this award without providing full and open competition is cited in FAR 13.106-1(b)(1)(i) which authorizes the government to award contracts when there is only one source available (e.g. urgency, exclusive licensing agreement, brand name or industrial mobilization).
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity